Mr. Henry Dubina reports

TELESCOPE ANNOUNCES APPOINTMENT OF DR. E. NEIL LEWIS TO THE BOARD OF DIRECTORS

Telescope Innovations Corp. has appointed Dr. Neil Lewis to its board of directors, effective Aug. 19, 2026.

Dr. Lewis received his PhD in chemistry from the Polytechnic of Wales in the United Kingdom and did his postdoctoral fellowship at the National Institutes of Health (NIH) in the United States. He was tenured by the NIH in 1992 holding the position of senior biophysical researcher. He is a fellow of the Royal Society of Chemistry (FRSC) and a chartered chemist (CChem) also conferred by the Royal Society of Chemistry. He is also a fellow of the Society of Applied Spectroscopy. Dr. Lewis was the founder or co-founder and chief executive officer of three technology companies, including Spectral Dimensions Inc., a company that developed chemical imaging systems for use by the pharmaceutical and other industries. He has authored more than 100 peer-reviewed papers and book chapters, and is the holder of numerous patents for other novel technologies currently in use by the analytical industry.

Henry Dubina, the company's chief executive officer, stated: "Dr. Neil Lewis brings a rare combination of scientific excellence, entrepreneurial success and global technology leadership. His pioneering work in spectroscopy, imaging and analytical sciences has transformed multiple industries, and his experience building and scaling innovative technology companies aligns perfectly with Telescope Innovations' mission to accelerate the development and commercialization of breakthrough solutions. In addition, we will leverage Neil's vast network across the instrument and investor community. We are thrilled to have his expertise helping shape the future of our company."

Grant of stock options

In connection with the appointment, the company has granted Dr. Lewis 100,000 incentive stock options to purchase up to 100,000 common shares of the company at an exercise price of 42 cents per share, exercisable for a period of five years from the date of grant, subject to a vesting schedule determined by the board. The options were granted pursuant to and are governed by the terms of the company's omnibus incentive plan and are subject to the policies of the Canadian Securities Exchange (the CSE).

About Telescope Innovations Corp.

Telescope is a chemical technology company developing intelligent automation technologies and scalable manufacturing processes for the pharmaceutical and chemical industry. The company builds and deploys reaction sampling systems for real-time analysis, flexible robotic platforms, and artificial intelligence software that improves experimental throughput, efficiency and data quality. The company's "self-driving labs" are fully autonomous, physical AI (artificial intelligence) platforms that plan, execute and analyze experiments far more efficiently than traditional manual approaches. Biopharmaceutical, high-value specialty chemical, and advanced materials companies utilize Telescope's products and services to accelerate the development and optimization of chemical processes, thereby cutting down time and costs from lab to market.

We seek Safe Harbor.